10x Genomics, Inc.

Key metrics

Financial performance

Over the last 8 fiscal years 10x Genomics, Inc.'s revenue grew from $71.08M to $642.82M, a compound annual growth rate of 31.7%. Net profit margin expanded from -26.4% to -6.8% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (652 filings)

Recent press releases

• 10x Genomics Reports First Quarter 2026 Financial Results2026-05-07

  PLEASANTON, Calif. , May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

• 10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference2026-04-29

  PLEASANTON, Calif. , April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time.

• 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 20262026-02-12

  PLEASANTON, Calif. , Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG ), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.

Similar companies

The largest companies sharing 10x Genomics, Inc.'s SEC industry classification (laboratory analytical instruments).